Drugs / Bone Marrow Concentrate

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT04205656 Jan 2020 → Jul 2024 overdue osteoarthritis, knee Steadman Philippon Research Institute Active not recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04559295 Nov 2018 → Mar 2020 arthropathy, intervertebral disk degenerative disorder, radiculopathy, spinal stenosis Stem Cures Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT03876795 Nov 2019 → Mar 2023 osteoarthritis, knee Rizzoli Orthopaedic Institute Completed No outcome recorded
Phase 41 trial
Phase 4 NCT03223701 Sep 2017 → Sep 2018 intervertebral disk degenerative disorder, spinal stenosis, spondylolisthesis Seton Healthcare Family Withdrawn No outcome recorded
Phase not applicable4 trials
NCT03790189 Jan 2019 → Jul 2021 chondromalacia, osteoarthritis, knee Istituto Clinico Humanitas Unknown No outcome recorded
NCT05191732 Aug 2018 → Jul 2020 Kaohsiung Medical University Chung-Ho Memorial Hospital Completed No outcome recorded
NCT03517761 Mar 2018 → Dec 2030 expected nervous system injury Regenexx, LLC Recruiting No outcome recorded
NCT01603836 Feb 2009 → Mar 2010 spondylosis Hospital Znojmo Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Bone Marrow Concentrate “the aim of the present pilot trial is to assess the safety and describe the clinical outcome following concurrent intra-articular and subchondral bone application of Bone...” NCT03790189
7

NCT03517761

NCT01603836

NCT04205656

NCT04559295

NCT03223701

NCT05191732

NCT03876795

Known as BMC “the aim of the present pilot trial is to assess the safety and describe the clinical outcome following concurrent intra-articular and subchondral bone application of Bone...” NCT03790189
2

“Bone marrow concentrate (BMC) (Dosage form: APA-15Q)” NCT05191732

“Biological: Bone Marrow Concentrate (BMC)” NCT04205656

Modality Cell therapy “The use of autologous mesenchymal stem cell (MSCs) in form of the BMC in combination with allograft is an effective option how to enhance the Posterolateral Fusion (PLF) healing.” NCT01603836
Route Other “in the interbody space of a TLIF” NCT03223701